Dimerix Limited ( (AU:DXB) ) has provided an update.
Dimerix Limited has announced the quotation of 147,275 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code DXB, effective March 3, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support ongoing development projects, potentially strengthening its position in the biotechnology market.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on the development of innovative therapies for unmet medical needs. The company is known for its work in drug discovery and development, particularly in the areas of kidney disease and other chronic conditions.
YTD Price Performance: 27.94%
Average Trading Volume: 2,473,980
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: A$243M
See more insights into DXB stock on TipRanks’ Stock Analysis page.